[HER2-positive breast cancer: standard and double targeted therapy]

V F Semiglazov; A A Bozhok; T Iu Semiglazova; A G Vasil'ev; A G Manikhas; V V Semiglazov; A A Bessonov; K S Nikolaev

[HER2-positive breast cancer: standard and double targeted therapy]

Vopr Onkol. 2013;59(3):341-6.

[Article in Russian]

Authors

V F Semiglazov, A A Bozhok, T Iu Semiglazova, A G Vasil'ev, A G Manikhas, V V Semiglazov, A A Bessonov, K S Nikolaev

PMID: 23909035

Abstract

Neoadjuvant systemic therapy is frequently used option for the systemic treatment for breast cancer. Inclusion in the regimen of targeted drugs as trastuzumab (Herceptin) and pertuzumab significantly improves outcomes in HER2-positive breast cancer patients. A certain part of HER2-positive patients can be cured by using only targeted drugs without chemotherapy.

Publication types

Clinical Trial

MeSH terms

Adult
Aged
Antibodies, Monoclonal, Humanized / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Biomarkers, Tumor / analysis*
Breast Neoplasms / chemistry
Breast Neoplasms / drug therapy*
Breast Neoplasms / pathology
Chemotherapy, Adjuvant
Female
Humans
Inflammatory Breast Neoplasms / drug therapy
Lapatinib
Middle Aged
Molecular Targeted Therapy / methods*
Neoadjuvant Therapy / methods*
Quinazolines / administration & dosage
Receptor, ErbB-2 / analysis*
Trastuzumab
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Biomarkers, Tumor
Quinazolines
Lapatinib
ERBB2 protein, human
Receptor, ErbB-2
pertuzumab
Trastuzumab